ANI Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ANI Pharmaceuticals (ANIP).

Price Target Range — 10 Quarters

Analyst Consensus — 11 Analysts

9Buy

2Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$94Upside to Avg. PT+29.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Perform	$85
Aug 10, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$124→$119
Aug 10, 2026	Canaccord Genuity	Gary Nachman	PT Cut	Hold	$91→$90
Jul 17, 2026	Canaccord Genuity	Gary Nachman	Initiate	Hold	$91
Jul 10, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$124
Jan 16, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$115→$124
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$100
Nov 10, 2025	Guggenheim	Vamil Divan	PT Raise	Buy	$114→$115
Oct 9, 2025	Truist Securities	Gregory Fraser	PT Raise	Hold	$77→$90
Sep 24, 2025	JP Morgan	Ekaterina Knyazkova	PT Raise	Overweight	$95→$115
Sep 17, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$93→$121
Sep 8, 2025	Guggenheim	Vamil Divan	PT Raise	Buy	$86→$114
Aug 11, 2025	Truist Securities	Gregory Fraser	PT Raise	Hold	$65→$77
Aug 8, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$84→$93
Jul 10, 2025	HC Wainwright & Co.	Brandon Folkes	Initiate	Buy	$84
May 12, 2025	Guggenheim	Vamil Divan	Maintained	Buy	$86
Apr 21, 2025	Truist Securities	Gregory Fraser	PT Raise	Hold	$62→$65
Apr 11, 2025	Guggenheim	Vamil Divan	Maintained	Buy	$86
Mar 17, 2025	HC Wainwright & Co.	Oren Livnat	Maintained	Buy	$94
Mar 14, 2025	Jefferies	Glen Santangelo	Initiate	Buy	$80

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

Oppenheimer analyst Les Sulewski initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Perform rating and announces Price Target of $85.

Benzinga Newsdesk

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.

Avi Kapoor

PRO
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold rating and announces Price Target of $91.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $124 price target.

Benzinga Newsdesk

ANI Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

ANI Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

PRO
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

PRO
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

PRO
Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

PRO
Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

People Also Watch

People Also Watch

ANI Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

ANI Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

PROGuggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

PROCanaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

PROCanaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

PROGuggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

People Also Watch

People Also Watch

PRO
Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

PRO
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

PRO
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

PRO
Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

PRO
Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target